Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Two Different Modifications of the Neuroblastoma x Glioma Hybrid Opiate Receptors Induced by N-Ethylmaleimide

NANCY E. LARSEN, DEBRA MULLIKIN-KILPATRICK and ARTHUR J. BLUME
Molecular Pharmacology September 1981, 20 (2) 255-262;
NANCY E. LARSEN
Department of Physiological Chemistry and Pharmacology, Roche Institute of Molecular Biology, Nutley, New Jersey 07110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DEBRA MULLIKIN-KILPATRICK
Department of Physiological Chemistry and Pharmacology, Roche Institute of Molecular Biology, Nutley, New Jersey 07110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ARTHUR J. BLUME
Department of Physiological Chemistry and Pharmacology, Roche Institute of Molecular Biology, Nutley, New Jersey 07110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Modification of membrane groups by N-ethylmaleimide (NEM) differentially inactivates the binding of the [3H]-labeled opioid peptide agonist [D-Ala2-Met5]-enkephalinamide (Dala2met5amide) and the opiate antagonists [3H]naltrexone and [3H]naloxone to NG108-15 opiate receptors. There appear to be at least two different NEM-sensitive groups involved. Alteration of one group by NEM prevents equally the binding of opiate agonists and antagonists and is seen as a reduction in the number of opiate binding sites. Furthermore, this process is first-order, and alteration of one of these groups is therefore sufficient to inactivate the receptor completely. The second group affected by NEM is at least 4-fold more sensitive to NEM, and in its altered state causes a selective reduction in the affinity of opiate agonists for these receptors. The affinity of at least one of the two antagonists tested (i.e., naloxone) actually is increased by 50% after modification of this group. With the opioid agonist Dala2met5amide these losses in affinity have been confirmed by both 3H-labeled peptide saturation studies and by studying the peptide competition against the [3H]naloxone binding. Both analyses indicate a 7-fold loss in affinity accompanying the modification of this group by NEM. All of the opiate agonists, including the enkephalins, β-endorphin, oxymorphone, normorphine, and etorphine, exhibit losses in affinity. The magnitude of these losses is not constant, but a property of the particular agonist, and is found with even the mixed agonist-antagonist pentazocine. Therefore these losses are proposed to be a general property of opiate agonists in this system; pure opiate antagonists along with the mixed antagonist-agonist cyclazocine do not show this loss. Modification of this second site is accompanied by (a) an increased sensitivity to the selective effects of cations (rank order Na+ > Li+ > K+ = choline) to decrease preferentially the agonist affinity and (b) a loss in sensitivity of the affinity of Dala2met5amide to GTP. The second NEM-sensitive site is therefore distal to the ligand binding domain and is proposed to be involved selectively in the formation of high-affinity agonist-receptor complexes.

ACKNOWLEDGMENTS The authors wish to thank R. J. Lefkowitz and A. De Lean, Duke University, for providing their computer program. Their assistance, along with that of A. Alexander, Management Information Service, Hoffmann-La Roche, Inc., in implementing this program is also gratefully acknowledged.

  • Copyright © 1981 by The American Society for Pharmacology and Experimental Therapeutics

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 20, Issue 2
1 Sep 1981
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Two Different Modifications of the Neuroblastoma x Glioma Hybrid Opiate Receptors Induced by N-Ethylmaleimide
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Two Different Modifications of the Neuroblastoma x Glioma Hybrid Opiate Receptors Induced by N-Ethylmaleimide

NANCY E. LARSEN, DEBRA MULLIKIN-KILPATRICK and ARTHUR J. BLUME
Molecular Pharmacology September 1, 1981, 20 (2) 255-262;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Two Different Modifications of the Neuroblastoma x Glioma Hybrid Opiate Receptors Induced by N-Ethylmaleimide

NANCY E. LARSEN, DEBRA MULLIKIN-KILPATRICK and ARTHUR J. BLUME
Molecular Pharmacology September 1, 1981, 20 (2) 255-262;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Human mAb 3F1 targeting the fuctional epitopes of Siglec-15
  • The regulation and mechanisms of ImKTX58 on KV1.3 channel
  • EIPA, HMA and SMN2 gene regulation
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics